Market Spotlight: Pancreatic Cancer
Market Spotlight: Pancreatic Cancer
$1,318.00
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were 453,200 incident cases of pancreatic cancer worldwide, and expects that number to increase to 495,900 incident cases by 2026.
- Incidence rates are highest in Europe and lowest in Africa, while the number of incident cases is highest in Asia, due to population size.
- The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor. These are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.
- The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II. Therapies in mid-to-late-stage development for pancreatic cancer focus on a wide variety of targets. The majority of drugs in mid-to-late-stage development for pancreatic cancer are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase II and Phase III trial results, and patent expirations.
- The overall likelihood of approval of a Phase I pancreatic cancer asset is 2.3%, and the average probability a drug advances from Phase III is 13.6%. Drugs, on average, take 10.3 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
- There have been 46 licensing and asset acquisition activities involving pancreatic cancer drugs during 2013–18. The $1,770m exclusive clinical collaboration agreement signed in 2014 between Bristol-Myers Squibb and Five Prime Therapeutics, to explore the combination of Opdivo with FPA008 in six tumor types including pancreatic cancer, was the largest deal during the period.
- The clinical trials distribution across Phase I–IV indicates that the majority of trials for pancreatic cancer have been in early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
- The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the pancreatic cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 91 trials.
- Roche leads the industry sponsors with the highest number of clinical trials for pancreatic cancer, followed by Eli Lilly.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Pancreatic cancer subtypes
10 TREATMENT
10 Surgery
11 Ablation or embolization
11 Radiation therapy
11 Chemotherapy
11 Targeted therapy
12 Immunotherapy
12 Drugs used specifically for treatment of PNETs
13 EPIDEMIOLOGY
16 MARKETED DRUGS
19 Approvals by country
22 PIPELINE DRUGS
42 RECENT EVENTS AND ANALYST OPINION
42 BL-8040 for pancreatic cancer (October 19, 2018)
43 AM0010 for pancreatic cancer (June 3, 2018)
45 ERY-ASP for pancreatic cancer (September 8, 2017)
47 Napabucasin for pancreatic cancer (June 3, 2017)
49 Demcizumab for pancreatic cancer (April 10, 2017)
51 PEGPH20 for pancreatic cancer (March 30, 2017)
52 ERY-ASP for pancreatic cancer (March 27, 2017)
54 PEGPH20 for pancreatic cancer (January 5, 2017)
57 KEY UPCOMING EVENTS
58 KEY REGULATORY EVENTS
58 Lutathera’s Broad Tumor Indication Aided By Expanded Access Data
58 Erytech Could Launch Several New Studies Following Pancreatic Cancer PhII Success
59 PROBABILITY OF SUCCESS
60 LICENSING AND ASSET ACQUISITION DEALS
60 Servier Acquires Shire Oncology Business For $2.4bn
60 Ipsen Pays $575m Upfront For Struggling Pancreatic Drug Onivyde
62 PARENT PATENTS
64 REVENUE OPPORTUNITY
66 CLINICAL TRIAL LANDSCAPE
67 Sponsors by status
68 Sponsors by phase
69 Recent events
70 BIBLIOGRAPHY
70 Prescription information
72 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of pancreatic cancer, 2017–26
22 Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
23 Figure 3: Pipeline drugs for pancreatic cancer, by company
23 Figure 4: Pipeline drugs for pancreatic cancer, by drug type
24 Figure 5: Pipeline drugs for pancreatic cancer, by classification
43 Figure 6: BL-8040 for Pancreatic Cancer: Phase IIa – COMBAT/KEYNOTE-202 (w/Keytruda)
45 Figure 7: AM0010 for Pancreatic Cancer: Phase I/Ib – 001
47 Figure 8: ERY-ASP for Pancreatic Cancer: Phase IIb – +/-SOC (EU)
49 Figure 9: Napabucasin for Pancreatic Cancer: Phase Ib/II – w/Gemcitabine/Nab-Paclitaxel (118)
51 Figure 10: Demcizumab for Pancreatic Cancer: Phase II – YOSEMITE
54 Figure 11: ERY-ASP for Pancreatic Cancer: Phase IIb – +/-SOC (EU)
56 Figure 12: PEGPH20 for Pancreatic Cancer: Phase II – HALO-202 (w/Abraxane + Gemcitabine)
57 Figure 13: Key upcoming events in pancreatic cancer
59 Figure 14: Probability of success in the pancreatic cancer pipeline
60 Figure 15: Licensing and asset acquisition deals in pancreatic cancer, 2013–18
62 Figure 16: Parent patents in pancreatic cancer, 2017–24
63 Figure 17: Parent patents in pancreatic cancer, 2024–29
63 Figure 18: Parent patents in pancreatic cancer, 2029–38
66 Figure 19: Clinical trials in pancreatic cancer
66 Figure 20: Top 10 drugs for clinical trials in pancreatic cancer
67 Figure 21: Top 10 companies for clinical trials in pancreatic cancer
67 Figure 22: Trial locations in pancreatic cancer
68 Figure 23: Pancreatic cancer trials status
69 Figure 24: Pancreatic cancer trials sponsors, by phase
LIST OF TABLES
14 Table 1: Incident cases of pancreatic cancer, 2017–26
17 Table 2: Marketed drugs for pancreatic cancer
20 Table 3: Approvals by country for pancreatic cancer
25 Table 4: Pipeline drugs for pancreatic cancer in the US
42 Table 5: BL-8040 for Pancreatic Cancer (October 19, 2018)
44 Table 6: AM0010 for Pancreatic Cancer (June 3, 2018)
46 Table 7: ERY-ASP for Pancreatic Cancer (September 8, 2017)
48 Table 8: Napabucasin for Pancreatic Cancer (June 3, 2017)
50 Table 9: Demcizumab for Pancreatic Cancer (April 10, 2017)
52 Table 10: PEGPH20 for Pancreatic Cancer (March 30, 2017)
53 Table 11: ERY-ASP for Pancreatic Cancer (March 27, 2017)
55 Table 12: PEGPH20 for Pancreatic Cancer (January 5, 2017)
64 Table 13: Historical global sales, by drug ($m), 2013–17
65 Table 14: Forecasted global sales, by drug ($m), 2018–22
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the